The Role of Direct Oral Anticoagulants in Cancer-Associated Venous Thromboembolism

Patients with cancer are at increased risk for developing venous thromboembolism (VTE) due to a combination of cancer-induced hypercoagulability, endothelial and vessel wall damage, and venous stasis. VTE risk is highest in patients with hematologic malignancies, lung cancer, gastrointestinal cancer...

Full description

Saved in:
Bibliographic Details
Published in:Journal for nurse practitioners 2019-07, Vol.15 (7), p.528-529
Main Authors: Hueftle, Brooke, Kator, Sarah
Format: Article
Language:English
Subjects:
Anticoagulants
Cancer therapies
Chemotherapy
Gastrointestinal cancer
Glycoproteins
Health risk assessment
Lung cancer
Pancreatic cancer
Patient compliance
Thromboembolism
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c283t-90e328e0070edff1d2b6b5119a6b427a45ee74d957359b6aaaed83cf2750094c3
container_end_page 529
container_issue 7
container_start_page 528
container_title Journal for nurse practitioners
container_volume 15
creator Hueftle, Brooke
Kator, Sarah
description Patients with cancer are at increased risk for developing venous thromboembolism (VTE) due to a combination of cancer-induced hypercoagulability, endothelial and vessel wall damage, and venous stasis. VTE risk is highest in patients with hematologic malignancies, lung cancer, gastrointestinal cancer, and pancreatic cancer. In addition, treatment-related factors further increase VTE risk. Cytotoxic chemotherapy can induce interleukin release promoting coagulation, and use of exogenous hormone replacement therapy (eg, tamoxifen) and immunomodulating agents (eg, lenalidomide) increase the risk of VTE through increased platelet aggregation. Other risk factors, including prechemotherapy platelet and leukocyte count, hemoglobin level, and body mass index, can be used to predict chemotherapy-associated thrombosis.
doi_str_mv 10.1016/j.nurpra.2019.02.015
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2250565928</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1555415519300236</els_id><sourcerecordid>2250565928</sourcerecordid><originalsourceid>FETCH-LOGICAL-c283t-90e328e0070edff1d2b6b5119a6b427a45ee74d957359b6aaaed83cf2750094c3</originalsourceid><addsrcrecordid>eNp9kEtLxDAUhYMoOI7-AxcB1603adPHRhjGJwwMDKO4C2l666R0mjFpBf-9GevaxX0s7jmH-xFyzSBmwLLbNu5Hd3Aq5sDKGHgMTJyQGSvyIgJRvJ-GXQgRpaGfkwvvW4CkyJJ0RjbbHdKN7ZDaht4bh3qga6c6uugHo636GDvVD56ani5Vr9FFC--tNmrAmr5hb0dPtztn95XFUJ3x-0ty1qjO49XfnJPXx4ft8jlarZ9elotVpHmRDFEJmPACAXLAumlYzausEoyVKqtSnqtUIOZpXYo8EWWVKaWwLhLd8FwAlKlO5uRm8j04-zmiH2RrR9eHSMm5AJGJMgTNSTpdaWe9d9jIgzN75b4lA3mkJ1s50ZNHehK4DPSC7G6SYfjgy6CTXhsMAOpfRrK25n-DHwhkeno</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2250565928</pqid></control><display><type>article</type><title>The Role of Direct Oral Anticoagulants in Cancer-Associated Venous Thromboembolism</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>ScienceDirect Freedom Collection</source><source>Social Science Premium Collection</source><source>Sociology Collection</source><creator>Hueftle, Brooke ; Kator, Sarah</creator><creatorcontrib>Hueftle, Brooke ; Kator, Sarah</creatorcontrib><description>Patients with cancer are at increased risk for developing venous thromboembolism (VTE) due to a combination of cancer-induced hypercoagulability, endothelial and vessel wall damage, and venous stasis. VTE risk is highest in patients with hematologic malignancies, lung cancer, gastrointestinal cancer, and pancreatic cancer. In addition, treatment-related factors further increase VTE risk. Cytotoxic chemotherapy can induce interleukin release promoting coagulation, and use of exogenous hormone replacement therapy (eg, tamoxifen) and immunomodulating agents (eg, lenalidomide) increase the risk of VTE through increased platelet aggregation. Other risk factors, including prechemotherapy platelet and leukocyte count, hemoglobin level, and body mass index, can be used to predict chemotherapy-associated thrombosis.</description><identifier>ISSN: 1555-4155</identifier><identifier>EISSN: 1878-058X</identifier><identifier>DOI: 10.1016/j.nurpra.2019.02.015</identifier><language>eng</language><publisher>Philadelphia: Elsevier Inc</publisher><subject>Anticoagulants ; Cancer therapies ; Chemotherapy ; Gastrointestinal cancer ; Glycoproteins ; Health risk assessment ; Lung cancer ; Pancreatic cancer ; Patient compliance ; Thromboembolism</subject><ispartof>Journal for nurse practitioners, 2019-07, Vol.15 (7), p.528-529</ispartof><rights>2019 Elsevier Inc.</rights><rights>2019. Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c283t-90e328e0070edff1d2b6b5119a6b427a45ee74d957359b6aaaed83cf2750094c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2250565928/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2250565928?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,12846,21394,21395,27924,27925,30999,33611,34530,43733,44115,74093,74511</link.rule.ids></links><search><creatorcontrib>Hueftle, Brooke</creatorcontrib><creatorcontrib>Kator, Sarah</creatorcontrib><title>The Role of Direct Oral Anticoagulants in Cancer-Associated Venous Thromboembolism</title><title>Journal for nurse practitioners</title><description>Patients with cancer are at increased risk for developing venous thromboembolism (VTE) due to a combination of cancer-induced hypercoagulability, endothelial and vessel wall damage, and venous stasis. VTE risk is highest in patients with hematologic malignancies, lung cancer, gastrointestinal cancer, and pancreatic cancer. In addition, treatment-related factors further increase VTE risk. Cytotoxic chemotherapy can induce interleukin release promoting coagulation, and use of exogenous hormone replacement therapy (eg, tamoxifen) and immunomodulating agents (eg, lenalidomide) increase the risk of VTE through increased platelet aggregation. Other risk factors, including prechemotherapy platelet and leukocyte count, hemoglobin level, and body mass index, can be used to predict chemotherapy-associated thrombosis.</description><subject>Anticoagulants</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Gastrointestinal cancer</subject><subject>Glycoproteins</subject><subject>Health risk assessment</subject><subject>Lung cancer</subject><subject>Pancreatic cancer</subject><subject>Patient compliance</subject><subject>Thromboembolism</subject><issn>1555-4155</issn><issn>1878-058X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><sourceid>ALSLI</sourceid><sourceid>HEHIP</sourceid><sourceid>M2S</sourceid><recordid>eNp9kEtLxDAUhYMoOI7-AxcB1603adPHRhjGJwwMDKO4C2l666R0mjFpBf-9GevaxX0s7jmH-xFyzSBmwLLbNu5Hd3Aq5sDKGHgMTJyQGSvyIgJRvJ-GXQgRpaGfkwvvW4CkyJJ0RjbbHdKN7ZDaht4bh3qga6c6uugHo636GDvVD56ani5Vr9FFC--tNmrAmr5hb0dPtztn95XFUJ3x-0ty1qjO49XfnJPXx4ft8jlarZ9elotVpHmRDFEJmPACAXLAumlYzausEoyVKqtSnqtUIOZpXYo8EWWVKaWwLhLd8FwAlKlO5uRm8j04-zmiH2RrR9eHSMm5AJGJMgTNSTpdaWe9d9jIgzN75b4lA3mkJ1s50ZNHehK4DPSC7G6SYfjgy6CTXhsMAOpfRrK25n-DHwhkeno</recordid><startdate>201907</startdate><enddate>201907</enddate><creator>Hueftle, Brooke</creator><creator>Kator, Sarah</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7QJ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>ASE</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>HEHIP</scope><scope>K6X</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201907</creationdate><title>The Role of Direct Oral Anticoagulants in Cancer-Associated Venous Thromboembolism</title><author>Hueftle, Brooke ; Kator, Sarah</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c283t-90e328e0070edff1d2b6b5119a6b427a45ee74d957359b6aaaed83cf2750094c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Anticoagulants</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Gastrointestinal cancer</topic><topic>Glycoproteins</topic><topic>Health risk assessment</topic><topic>Lung cancer</topic><topic>Pancreatic cancer</topic><topic>Patient compliance</topic><topic>Thromboembolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hueftle, Brooke</creatorcontrib><creatorcontrib>Kator, Sarah</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>Social Science Premium Collection</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Sociology Collection</collection><collection>British Nursing Index</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Sociology Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Journal for nurse practitioners</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hueftle, Brooke</au><au>Kator, Sarah</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Role of Direct Oral Anticoagulants in Cancer-Associated Venous Thromboembolism</atitle><jtitle>Journal for nurse practitioners</jtitle><date>2019-07</date><risdate>2019</risdate><volume>15</volume><issue>7</issue><spage>528</spage><epage>529</epage><pages>528-529</pages><issn>1555-4155</issn><eissn>1878-058X</eissn><abstract>Patients with cancer are at increased risk for developing venous thromboembolism (VTE) due to a combination of cancer-induced hypercoagulability, endothelial and vessel wall damage, and venous stasis. VTE risk is highest in patients with hematologic malignancies, lung cancer, gastrointestinal cancer, and pancreatic cancer. In addition, treatment-related factors further increase VTE risk. Cytotoxic chemotherapy can induce interleukin release promoting coagulation, and use of exogenous hormone replacement therapy (eg, tamoxifen) and immunomodulating agents (eg, lenalidomide) increase the risk of VTE through increased platelet aggregation. Other risk factors, including prechemotherapy platelet and leukocyte count, hemoglobin level, and body mass index, can be used to predict chemotherapy-associated thrombosis.</abstract><cop>Philadelphia</cop><pub>Elsevier Inc</pub><doi>10.1016/j.nurpra.2019.02.015</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1555-4155
ispartof Journal for nurse practitioners, 2019-07, Vol.15 (7), p.528-529
issn 1555-4155
1878-058X
language eng
recordid cdi_proquest_journals_2250565928
source Applied Social Sciences Index & Abstracts (ASSIA); ScienceDirect Freedom Collection; Social Science Premium Collection; Sociology Collection
subjects Anticoagulants
Cancer therapies
Chemotherapy
Gastrointestinal cancer
Glycoproteins
Health risk assessment
Lung cancer
Pancreatic cancer
Patient compliance
Thromboembolism
title The Role of Direct Oral Anticoagulants in Cancer-Associated Venous Thromboembolism
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T02%3A55%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Role%20of%20Direct%20Oral%20Anticoagulants%20in%20Cancer-Associated%20Venous%20Thromboembolism&rft.jtitle=Journal%20for%20nurse%20practitioners&rft.au=Hueftle,%20Brooke&rft.date=2019-07&rft.volume=15&rft.issue=7&rft.spage=528&rft.epage=529&rft.pages=528-529&rft.issn=1555-4155&rft.eissn=1878-058X&rft_id=info:doi/10.1016/j.nurpra.2019.02.015&rft_dat=%3Cproquest_cross%3E2250565928%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c283t-90e328e0070edff1d2b6b5119a6b427a45ee74d957359b6aaaed83cf2750094c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2250565928&rft_id=info:pmid/&rfr_iscdi=true